Headlines about Cardiome Pharma (NASDAQ:CRME) (TSE:COM) have trended somewhat negative this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cardiome Pharma earned a media sentiment score of -0.01 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 47.1372626191796 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of brokerages recently issued reports on CRME. ValuEngine upgraded Cardiome Pharma from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. HC Wainwright set a $10.00 target price on Cardiome Pharma and gave the stock a “buy” rating in a report on Wednesday, April 4th. Finally, Canaccord Genuity set a $5.00 target price on Cardiome Pharma and gave the stock a “buy” rating in a report on Wednesday, March 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $5.67.
Cardiome Pharma traded down $0.05, hitting $2.33, during trading hours on Friday, Marketbeat.com reports. 90,444 shares of the company traded hands, compared to its average volume of 135,322. The company has a current ratio of 3.97, a quick ratio of 3.99 and a debt-to-equity ratio of 4.31. Cardiome Pharma has a one year low of $1.29 and a one year high of $4.84. The stock has a market cap of $81.25 million, a PE ratio of -2.59 and a beta of 0.19.
Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last issued its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). Cardiome Pharma had a negative net margin of 125.98% and a negative return on equity of 164.75%. The company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million. sell-side analysts forecast that Cardiome Pharma will post -0.77 earnings per share for the current fiscal year.
About Cardiome Pharma
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients.
Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.